Celldex Reports Fourth Quarter and Fiscal 2012 Financial Results
"Celldex ended 2012 reporting positive data from four clinical programs at major medical meetings, including final results from our Phase 2b study of CDX-011 in metastatic breast cancer," said
Marucci continued, "Importantly, we begin 2013 well-financed with a current cash position that will support operations and clinical development through 2015. To that end, in addition to the CDX-011 accelerated approval study, we will also initiate new clinical studies and expansion studies for four other Celldex programs in 2013. We expect data from three clinical studies by year end—including from our Phase 2 study of rindopepimut with Avastin® in refractory glioblastoma. To close what will already be a very busy year, we also look forward to completing enrollment in the rindopepimut ACT IV registration trial in frontline glioblastoma."
Fourth Quarter and Recent Highlights
Presented positive final results from the Phase 2b EMERGE study of CDX-011 in patients with GPNMB-expressing, advanced, heavily pretreated breast cancer at the San Antonio Breast Cancer Symposium in December. Progression free and overall survival benefits were demonstrated in the subgroup of patients with triple negative disease that also over-expressed GPNMB, and strong trends towards benefits were seen in all patients with over-expression of GPNMB.
Announced impressive three-year survival data across three Phase 2 studies of rindopepimut, in EGFRvIII-positive glioblastoma at the
Society for Neuro-OncologyAnnual Meeting in November. In addition, Celldex announced a new contemporary historical control data set compiled from the Radiation Therapy Oncology Group(RTOG)'s Phase 3 0525 study that continues to demonstrate that patients with EGFRvIII-positive glioblastoma fare worse than the general glioblastoma patient population. Importantly, the data set provides further confidence in the ACT IV registration study design.
Continued to open clinical sites to support enrollment in the Phase 3 ACT IV study and the Phase 2 ReACT study of rindopepimut in glioblastoma. In total, there are now more than 142 clinical sites around the world that are actively screening patients to participate in the ACT IV study. The ReACT study is also well-positioned, with all 25 study sites actively screening to date.
Presented positive results from the Phase 1 study of CDX-1401 in solid tumors at the
Society for Immunotherapy of CancerAnnual Meeting in October 2012. The study identified a well-tolerated and immunogenic regimen.
Completed enrollment in the Phase 1 portion of the CDX-1127 solid tumor arm. CDX-1127 was determined to be well-tolerated to date, including at the highest dose level. Celldex continues to enroll patients in the dose escalation portion of the lymphoma and leukemia arm.
Presented final results from a Phase 1 multi-dose study of CDX-301 (rhuFlt3L) in healthy volunteers in an oral presentation at the
American Society for Blood and Marrow Transplantation2013 BMT Tandem Meetings in February 2013. The study demonstrated that CDX-301 was well-tolerated and can effectively mobilize hematopoietic cell populations in healthy volunteers.
Raised net proceeds of
$114.1 millionin the first quarter of 2013 to support operations and clinical development activities through 2015.
Key 2013 Objectives
Complete global recruitment in the ACT IV registration study of rindopepimut in front-line glioblastoma and in the ReACT study of rindopepimut in combination with Avastin in patients with recurrent/refractory EGFRvIII-positive glioblastoma. Announce results from the ReACT study by year end.
Initiate a pivotal, randomized, accelerated approval study of CDX-011 in patients with triple negative breast cancers that over-express GPNMB in the second half.
Complete enrollment of the Phase 1 dose-escalation and expansion studies of CDX-1127 in patients with hematologic cancers and initiate expansion cohorts in both solid tumors and hematologic malignancies. Report data from this study in the second half.
Initiate a pilot study of CDX-1135 in dense deposit disease, an orphan renal disease in children and young adults, with data expected by year end.
Initiate a pilot clinical study of CDX-301 in hematopoietic stem cell transplant in the second half.
Initiate a Phase 2 study of CDX-1401 in combination with CDX-301 sponsored by the Cancer Immunotherapy Trials Network of the
National Cancer Institute.
Fourth Quarter and Year-to-Date Financial Highlights
The increase in net loss of
The net loss of
Webcast and Conference Call
Celldex will host a conference call and live audio webcast at
A replay of the call will be available approximately two hours after the live call concludes through
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization (by Celldex and others) of rindopepimut (CDX-110), CDX-011, CDX-1135, CDX-1401, CDX-1127, CDX-301, Belinostat and other products. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our limited cash reserves and our ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; our ability to adapt APC Targeting TechnologyTM to develop new, safe and effective therapeutics for oncology and infectious disease indications; our ability to successfully complete product research and further development of our programs; the uncertainties inherent in clinical testing; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage research and development efforts for multiple products at varying stages of development; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Avastin® is a registered trademark of
|CELLDEX THERAPEUTICS, INC.|
|(In thousands, except per share amounts)|
|CONSOLIDATED STATEMENTS||Quarter Ended||Year Ended|
|OF OPERATIONS DATA||
|Product Development and|
|Licensing Agreements||$ 43||$ 45||$ 146||$ 110|
|Contracts and Grants||53||30||281||36|
|Research and Development||13,748||9,824||47,398||32,439|
|General and Administrative||2,644||2,343||10,016||9,193|
|Amortization of Acquired Intangible Assets||254||291||1,090||1,913|
|Total Operating Expense||20,197||14,816||69,279||52,664|
|Investment and Other Income, Net||94||89||530||396|
|Net Loss||$ (16,807)||$ (12,732)||$ (59,123)||$ (44,799)|
|Basic and Diluted Net Loss|
|per Common Share||$ (0.27)||$ (0.29)||$ (1.02)||$ (1.13)|
|Weighted Average Common Shares Outstanding||62,544||44,175||57,713||39,501|
|Cash, Cash Equivalents and Marketable Securities||$ 83,962||$ 53,312|
|Other Current Assets||1,152||1,372|
|Property and Equipment, net||7,205||9,093|
|Intangible and Other Assets, net||33,222||34,217|
|Total Assets||$ 125,541||$ 97,994|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Current Liabilities||$ 17,685||$ 14,298|
|Total Liabilities and Stockholders' Equity||$ 125,541||$ 97,994|
Sarah CavanaughVice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc.(781) 433-3161 email@example.com
News Provided by Acquire Media